Innodem Neurosciences

What Innodem Neurosciences does

Innodem Neurosciences is a privately held Canadian digital health company, founded in 2016 in Montreal and operating as 10032506 Canada Inc. The company has developed patented tablet-based eye-tracking technology that uses the front-facing camera of an off-the-shelf iPad Pro in visible light to capture eye movements and gaze patterns, eliminating the need for specialized infrared hardware. Its core product, ETNA-MS, is a Class II Software as a Medical Device (cleared by Health Canada in 2024, FDA Breakthrough Device Designation in 2022) that administers sub-10-minute non-invasive eye-tracking tests and uses proprietary machine learning models hosted on ETNA-Cloud to generate EDSS and SDMT scores for tracking multiple sclerosis disease progression. A broader ETNA Clinical Apps portfolio extends the platform into Alzheimer's, Parkinson's, cancer-related cognitive impairment, ALS, mild traumatic brain injury, and Friedreich's ataxia, while the Pigio consumer app applies the same underlying eye-tracking IP for gaze-to-speech communication in voiceless ICU patients.

Innodem monetizes primarily through enterprise B2B channels: multi-year commercial framework agreements with pharmaceutical companies (most notably a multimillion-dollar deal with Novartis Pharmaceuticals Canada covering a pan-Canadian pilot across up to 15 sites and an observational trial through 2027), subscription pricing for the ETNA-MS SaMD accessed via the Apple App Store with clinician authorization, and licensing/royalty arrangements for clinical trial endpoint use. Distribution combines direct enterprise sales to neurologists and MS clinics, pharmacy partner programs in Quebec via MS Canada, and clinical research collaborations with McGill University / Montreal Neuro Hospital. The company is backed by Morningside Ventures (Series A lead) and operates with a small team of 1-10 employees, relying on a senior leadership group that combines clinical neurology, AI research, and software engineering.

Name

Innodem Neurosciences

Legal name

10032506 Canada Inc.

Website

https://innodemneurosciences.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

Innodem Neurosciences is a Montreal-based digital health company that has developed patented tablet-based eye-tracking technology (ETNA™) using an iPad Pro front-facing camera and proprietary machine learning models to generate neurological biomarkers for tracking multiple sclerosis and other neurodegenerative diseases, selling primarily to pharmaceutical companies and neurology clinics.

Ownership category

akta.pro rank

Product category

Digital Health / Neurology Diagnostics Software

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)

akta.pro secondary industries

Medical Imaging AI (HDAAAEAH), Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity) (HLAHAJAC)

Keywords

• Digital biomarkers
• Eye tracking technology
• Neurological assessment software
• Medical device software
• Neurodegenerative disease monitoring

Headquarters

HQ city

Montréal

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. ETNA™-MS Commercial Sales: Sale of ETNA-MS as a Software as a Medical Device (SaMD, Class II). The product provides EDSS and SDMT scores for tracking MS disease progression. Cleared for commercial use by Health Canada.
2. Pharmaceutical Partnership Agreements: Multi-year commercial framework agreements with pharmaceutical companies like Novartis for clinical trials, pilot programs, and commercialization support. The company has signed multimillion-dollar agreements for ETNA technology deployment in MS patient monitoring.
3. Pigio™ App: Consumer health app with Gaze-to-Speech technology for voiceless patients to communicate using eye movements. Available on iOS iPad App Store.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Innodem Neurosciences develops and commercializes patented mobile eye-tracking software that turns a standard iPad Pro into a medical device for assessing neurological disease. Its core offerings include ETNA™-MS, a Class II Software as a Medical Device cleared by Health Canada that delivers EDSS and SDMT scores for multiple sclerosis, the underlying ETNA™-Cloud analytics platform, and Pigio™, a Gaze-to-Speech consumer app for voiceless patients. The platform extracts Eye Movement Biomarkers (EMBs) and Gaze Mapping Biomarkers (GMBs) analyzed by proprietary machine-learning models to enable objective, quantitative neurological assessment and remote patient monitoring.

Product overview

Innodem Neurosciences offers a platform-plus-modules architecture centered on its patented ETNA™ (Eye Tracking Neurological Assessment) technology. The core system consists of the ETNA™-MS medical device (for MS) and ETNA™-Cloud backend, with additional clinical trial apps (ETNA™ Clinical Apps) for Alzheimer's, Parkinson's, CRCI, and other conditions. The platform transforms standard iPad Pro tablets into eye-tracking medical devices that extract Eye Movement Biomarkers (EMBs) and Gaze Mapping Biomarkers (GMBs), processed by AI/machine learning to generate disease severity scores. Pigio™ represents an earlier product line using the same eye-tracking technology for communication assistance in voiceless patients. All products share the foundational eye-tracking software and cloud AI infrastructure.

Differentiator

Problem solved

Functional benefit

Brands

• ETNA™-MS: Eye-Tracking Neurological Assessment for Multiple Sclerosis - a Class II Software as a Medical Device (SaMD) that administers non-invasive eye-tracking tests to provide EDSS and SDMT scores for tracking MS disease progression.
• Pigio™
• ETNA™-Cloud

Products and services

• ETNA™-MS Class II Software as a Medical Device (SaMD) that turns an iPad Pro into a non-invasive eye-tracking medical device for multiple sclerosis. Administers a sub-10-minute eye-tracking test, extracts hundreds of eye movement parameters, and uses cloud-based ML to deliver EDSS scores (1.0–7.0) and SDMT cognitive scores for tracking MS disease progression. Intended for use by neurologists, MS clinics, and patients (including at-home self-testing).
• ETNA™-Cloud Cloud-based data-management and analytics backend for healthcare providers. Runs clinically validated and locked AI/ML models that combine eye-movement metrics with patient information (age, mobility level, T25-FW) to produce EDSS and SDMT scores. ISO/IEC 27001, PIPEDA and HIPAA compliant. Used internally to power ETNA-MS clinical results; not offered as an external API.
• Pigio™ Patented mobile consumer-health app with Gaze-to-Speech™ technology that allows voiceless patients (e.g., conscious but intubated or paralyzed ICU patients) to communicate using only eye movements. Pigio™ ICU targets ICU communication; Pigio™ Pro adds media/entertainment access. Distributed via Apple App Store for iPad.

Quantifiable outcome

• Up to 84% variance explained in clinical outcome measures using eye movement parameters in MS patients
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Partnerships

Twelve partnerships are on record, tiered flagship, core, major and minor.

• Novartis Pharmaceuticals Canada Inc.flagshipStrategic or Co-development Partner · 7 September 2023Multi-year Commercial Framework Agreement for ETNA-MS technology. Includes pan-Canadian pilot project in up to 15 sites. Novartis is supporting ongoing observational trials and commercialization efforts for MS patient monitoring. Partnership aims to improve standard of care in MS through biomarker-based disease progression detection.
• Novartis Pharmaceuticals Canada Inc.flagshipStrategic or Co-development Partner · 5 October 2021Initial multi-year partnership agreement for breakthrough clinical trial to help people living with multiple sclerosis. Trial involves bi-weekly patient self-testing with ETNA technology, correlating data with EDSS, BICAMS, and MSFC scores until 2027.
• Mila - Quebec Artificial Intelligence InstitutecoreTechnology or IntegrationAI research partnership for machine learning algorithm development and deep learning technology advancement in eye-tracking biomarker analysis.
• McGill University / Montreal Neuro HospitalcoreStrategic or Co-development PartnerAcademic partnership for clinical trials and research. Dr. Étienne de Villers-Sidani serves as Associate Professor and Director of Neuroplasticity and Sensory Biomarking Laboratory. Access to well-phenotyped patient data for algorithm training.
• MCRA (McCright & Associates Regulatory Affairs)coreImplementation/ SI/ Consulting PartnerRegulatory consulting partner for FDA Breakthrough Device Designation and deNovo submission preparation. MCRA serves as regulatory consultants for the company's medical device software.
• MS CanadamajorStrategic or Co-development PartnerPartnership for ETNA-MS Pilot Project deployment in partner pharmacies across Quebec. Collaboration on patient access and monitoring programs for multiple sclerosis community.
• Centre for Research on Brain-Language-Neuroscience (CRBLM)minorStrategic or Co-development PartnerAcademic research collaboration in neuroscience and brain-language research.
• ALS CanadaminorStrategic or Co-development PartnerPartnership for exploring eye-tracking applications in ALS disease monitoring and research.
• Gowling WLGminorOthersLegal and intellectual property consulting partner.
• Alzheimer Society CanadaminorStrategic or Co-development PartnerPartnership for Alzheimer's disease research and eye-tracking biomarker development.
• EY (Ernst & Young)minorOthersProfessional services partnership.
• Parkinson QuebecminorStrategic or Co-development PartnerPartnership for Parkinson's disease research and patient outreach.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• RightEye: US-based company that uses tablet- and web-camera-based eye tracking to deliver objective neurological, visual and brain-health assessments to clinicians and sports-medicine providers, directly overlapping with Innodem's iPad-based EMB/GMB approach.
• Neurolign (formerly Neuro Kinetics): Specializes in eye-tracking-based diagnostics for neurological and vestibular disorders, with FDA-cleared devices for clinical use — a more established peer in the same eye-tracking-as-neurology-assessment category.
• ViewMind: Eye-tracking-based digital biomarker company focused on neurological and cognitive disorders (Alzheimer's, MS, etc.) using standardized visual tasks — a direct functional and technology peer to Innodem's ETNA platform.
• SyncThink (EYE-SYNC): Developer of FDA-cleared eye-tracking-based neurological assessment tools (originally for concussion/mTBI) that similarly translate oculomotor metrics into clinical decision support, competing with ETNA for the same clinical workflow and regulatory positioning.

Broad incumbents

• Cambridge Cognition: Provider of CANTAB cognitive assessment platform widely used in CNS clinical trials (including MS) and clinical practice — a broad incumbent in digital CNS assessment whose pharma-trial channel overlaps with Innodem's Novartis-style motion.
• Cogstate: Listed (ASX:CGS) computerized cognitive testing company used in clinical trials and clinical practice for neurological assessment, including MS — an established incumbent in the adjacent computerized neuro-assessment category that often appears on the same pharma RFPs.
• Roche (Floodlight MS): Roche/Genentech's Floodlight MS is a smartphone-based digital-biomarker app for MS disease monitoring used in clinical trials and label-enabling studies; a broad pharma incumbent with vastly greater resources targeting the same MS monitoring use case.

Emerging players

• C. Light Technologies: AI-driven eye-tracking analytics company developing ocular-motor biomarkers for neurological disease monitoring, including MS and neurodegeneration — a smaller emerging peer in the same digital-oculomotor-biomarker space.
• Linus Health: Digital cognitive assessment platform (built partly from the Savonix acquisition) used for early detection of Alzheimer's and other neurodegenerative conditions — an emerging peer in the digital-biomarker-for-cognition space overlapping with Innodem's GMB work.
• Octave Bioscience: Develops a multi-modal MS disease-activity measurement platform (blood-based biomarkers plus digital metrics) and is commercializing into MS clinics and pharma trials — an emerging peer in objective MS disease monitoring that may complement or compete with ETNA-MS.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/shopify
• Instagraminstagram.com/shopify
• Xx.com/InnodemNeuro

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Innodem Neurosciences